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Abstract
The conjugate of paclitaxel (PTX) and docosahexaenoic acid has entered into clinical trials. 
However, the most recent clinical outcomes fell short of expectations, due to the extremely slow 
drug release from the hydrophobic conjugates. Herein, we report a novel prodrug-based 
nanoplatform self-assembled by the disulfide bond linked conjugates of PTX and oleic acid (OA) 
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for rapid and differential release of PTX in tumor cells. This redox-responsive prodrug-
nanosystem demonstrates multiple therapeutic advantages, including one-step facile fabrication, 
high drug-loading efficiency (56%, w/w), on-demand drug release responding to redox stimuli, as 
well as favorable cellular uptake and biodistribution. These advantages result in significantly 
enhanced antitumor efficacy in vivo, with the tumor almost completely disappearing in mice. Such 
a uniquely engineered prodrug-nanosystem has great potential to be used as potent 
chemotherapeutic nanomedicine in clinical cancer therapy.
Graphical Abstract
To bridge the gap between hydrophobic lipid prodrugs of PTX and favorable antitumor efficacy, a 
smart redox-sensitive prodrug-nanosystem has been designed. The uniquely engineered stimulus-
responsive prodrug nanoassemblies, with high drug loading (over 50%, w/w), on-demand drug 
release within tumor cells and potent antitumor efficacy, hold great potential to be used as a 
promising chemotherapeutic nanomedicine in cancer therapy.
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1. Introduction
Although the fields of nanotechnology and biomaterials have been extensively explored for 
anticancer drug delivery, the clinical outcomes of the available nanoparticulate drug delivery 
systems (Nano-DDS) were not as good as expected.[1–3] The limiting clinical efficacy of 
these conventional Nano-DDS can be attributed to several disadvantages, including low 
drug-loading capacity (<10%, w/w), poor stability, potential crystallization during storage, 
premature drug leakage from vehicles, and serious excipient-induced toxicity.[4] Therefore, 
it’s necessary to develop high-efficiency vehicles for systemic delivery of anticancer drugs.
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Fatty acids, especially unsaturated fatty acids (UFAs), have been widely used to develop 
fatty acids-based conjugates for healthcare applications.[5–7] For cancer therapy, a wide 
range of conjugates based on UFAs have been designed for anticancer drug delivery. Among 
them, three conjugates have entered clinical trials and hold a great potential to be applied in 
clinicals in the future, including docosahexaenoic acid (DHA)-PTX, Elaidic acid-cytarabine 
and Elaidic acid-gemcitabine.[8–10] The rational design of UFAs-based conjugates can be 
attributed to the following aspects: (i) to enhance the stability of anticancer drugs,[10, 11] the 
conjugation of anticancer drugs with UFAs can protect the fragile groups of the parent drug 
from being metabolized in vivo; (ii) to improve lipophilicity of drugs,[11] hydrophilic drugs 
can not easily pass through the bilayer membrane via passive diffusion, resulting in poor 
bioavailability in target sites; (iii) to achieve natural targeting effects to tumors,[12,13] several 
studies have suggested an increased fatty acid uptake in tumors as nutrient sources; (iv) to 
enhance the chemotherapeutic response of anticancer drugs,[14–17] some UFAs could 
significantly sensitize anticancer drugs-induced apoptosis of human tumor cells; and (v) to 
minimize side effects of anticancer drugs at high doses,[18] low cytotoxicity and sustained 
release of the parent drugs make UFAs-based anticancer conjugates reduced side effects. 
Therefore, developing advanced UFAs-based DDS holds great potential for cancer therapy.
Paclitaxel (PTX) has been widely utilized in clinic for the treatment of a wide range of 
cancer, including non-small cell lung cancer, breast cancer, ovarian cancer, and malignant 
melanoma.[19] The antitumor mechanism of PTX can be attributed to interacting with 
microtubules to prevent depolymerization.[20] Taxol, the first commercially available 
formulation of PTX, has long been criticized for its serious excipient-associated toxicities. 
In response to these problems, various drug delivery strategies have been developed to 
improve the drug availability and to enhance the antitumor efficiency of PTX, including 
designing prodrugs and Nano-DDS.[4,21] Among these strategies for PTX delivery, lipid 
prodrugs of PTX and fatty acids have been widely investigated. The conjugate of PTX and 
DHA has been under phase III clinical trials.[8,22] Unfortunately, PTX-DHA showed no 
significant advance in inhibiting tumor growth of patients in clinical trials,[8] due to the 
inefficient release of PTX from the hydrophobic conjugate.[18]
Tumor cells are characterized as elevated intracellular glutathione (GSH) level, and the 
cytosolic GSH concentration in tumor cells is several times higher than that in normal 
cells.[23,24] The elevated GSH level in tumor cells has been extensively explored for 
designing stimulus-sensitive Nano-DDS, and disulfide bond has been widely used as a 
redox-responsive linkage to facilitate a rapid and differential release of anticancer drugs in 
tumor cells.[24,25] We thereby hypothesized that designing a disulfide bond inserted prodrug 
of PTX and fatty acids would facilitate the rapid and differential release of free PTX from 
hydrophobic conjugates.
Based on this rationale, a novel redox-responsive conjugate of PTX and oleic acid (OA), 
denoted as PTX-S-S-OA, was synthesized by covalently connecting PTX and OA via a 
disulfide bond. An ester prodrug (PTX-OA) was synthesized as the non-sensitive conjugate. 
The unsaturated alkyl chains of UFAs, e.g. OA in these two conjugates, would benefit the 
sufficient structural flexibility conferred by the double bond of OA. However, some UFAs 
with too many double bonds (e.g. DHA with six double bonds) would be more easily 
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oxidized and degraded, resulting in inferior chemical stability of UFAs-based conjugates. In 
addition, it has been reported that the combination of OA and PTX can significantly enhance 
the chemosensitivity of PTX.[15] That’s the reason why OA was selected for the rational 
design of PTX conjugates in the present study. Interestingly, both PTX-S-S-OA and PTX-
OA could self-assemble into nanoparticles (NPs) in deionized water. Therefore, a novel 
prodrug-nanosystems was developed by integrating prodrug strategy and nanotechnology 
into one system to facilitate systemic delivery of PTX. Tocopheryl polyethylene glycol 2000 
succinate (TPGS2k) was added to the prodrug-nanosystem for improved colloidal stability 
and prolonged blood circulation. The PEGylated prodrug nanoassemblies of PTX-S-S-OA 
(PTX-S-S-OA/TPGS2k NPs), demonstrated significantly high drug loading (56% of PTX, 
w/w) as well as on-demand drug release responding to redox stimuli. After internalization 
into the tumor cells, the elevated intracellular glutathione (GSH) level triggers the cleavage 
of the disulfide bond,[23] resulting in the rapid and differential release of PTX. Which in turn 
facilitate PTX-induced apoptosis of tumor cells. The high drug loading efficiency and rapid 
release of free PTX from the hydrophobic conjugate within the tumor cells would 
significantly improve the therapeutic efficacy. Although disulfide bond has been widely used 
as redox-sensitive linkage for designing anticancer conjugates,[25–27] including PTX 
conjugates, to our knowledge, this is the first attempt to develop prodrug-nanoplatform 
based on disulfide bond-bridged hydrophobic conjugates of PTX and fatty acids for systemic 
delivery of PTX. In such a uniquely engineered prodrug-nanosystem, prodrug strategy and 
nanotechnology are integrated into one system to facilitate the chemotherapy efficiency of 
PTX.
2. Results and Discussions
2.1 Design and Synthesis of Prodrugs
To test our hypothesis, a novel redox-sensitive PTX-fatty acid conjugates (PTX-S-S-OA) 
was synthesized by conjugating OA to PTX via disulfide bond as a linkage (Scheme S1). 
Additionally, OA was directly coupled to the C2’-oxygen of paclitaxel via a simple ester 
bond to obtain an ester prodrug (PTX-OA). The chemical structures of PTX-S-S-OA and 
PTX-OA were confirmed by MS, 1H NMR and IR (Figure S1and S2).
2.2. Self-Assembly of Prodrugs in Water
A simple nano-precipitation method was used to prepared nanoassemblies. Interestingly, 
both PTX-S-S-OA and PTX-OA were found to spontaneously assemble into uniform 
nanoparticles in deionized water. In contrast, when nanoprecipitation was performed 
utilizing free PTX instead of the fatty acid conjugates, PTX immediately precipitated, 
suggesting the crucial role of the fatty acid moiety in the self-assembly process. As shown in 
Figure 1 and Table S1, these prodrug nanoassemblies showed spherical morphology with a 
diameter of around 100 nm (Figure 1 and S3). The PEGylated formulations (15% of 
TPGS2k, w/w) exhibited a slightly increased particle size of about 10 nm when compared 
with the non-PEGylated ones (Table S1). Nanoparticles with a size of around 100 nm are 
supposed to be suitable for enhanced tumor accumulation via the enhanced permeation and 
retention (EPR) effect.[28] In this precisely engineered prodrug-nanosystem, the conjugates 
simultaneously play two roles as building blocks for nanostructure and the encapsulated 
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drug. In other words, the conjugates (PTX-OA and PTX-S-S-OA) themselves act as both 
carriers and cargos. Additionally, OA only accounts for a small proportion in the whole 
conjugates due to its low molecular weight (~282) when compared with PTX (~853). As a 
result, these prodrug nanoassemblies showed impressively high drug loading efficiency (56–
66% of PTX, w/w) (Table S1). High drug loading is of a great importance for high 
therapeutic efficacy and low excipient-associated toxicities. Furthermore, the PEGylated 
prodrug nanoassemblies (PTX-S-S-OA/TPGS2k NPs and PTX-OA/TPGS2k NPs) were 
highly stable in PBS (pH 7.4) supplemented with 10% FBS at 37 °C, with no significant 
variation of their mean diameter over a period of 12 h (Figure S4A). They also showed good 
physical stability for an extended period of time (3 months) at 4 °C (Figure S4B).
2.3 In Vitro Hydrolysis of Prodrugs from Nanoassemblies
Dithiothreitol (DTT), a prevailing GSH simulatant, was utilized to investigate the reductive 
responsiveness of PTX-S-S-OA/TPGS2k NPs. As shown in Figure 2, less than 27% of PTX 
was released from PTX-S-S-OA/TPGS2k NPs within 12 h in PBS (pH 7.4) without DTT, but 
more than 90% of PTX was released within 2 h in the presence of 10 mM DTT. The HPLC 
profile indicated that the released compound was free PTX (data not shown). By contrast, 
there was no PTX released from PTX-OA/TPGS2k NPs after 24 h incubation in PBS (pH 
7.4) either with or without DTT. These results suggest that the drug release from ester 
prodrug (PTX-OA) is extremely slow, and designing stimuli-sensitive prodrug is an effective 
strategy to respond to the extremely slow drug release from the hydrophobic prodrugs of 
PTX and fatty acids. The rapid and differential drug release within tumor cells would result 
in enhanced antitumor activity.
2.4 In Vitro Cytotoxicity Induced by Released PTX
The in vitro cytotoxicity was evaluated in KB-3-1, H460 and OVCAR-8 cells at varying 
equivalent PTX concentrations using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay. As shown in Figure 3A and Figure S5, PTX-OA/TPGS2k 
NPs exhibited no cytotoxicity in all three cell lines within the studied range of drug 
concentrations, due to the extremely slow hydrolysis rate of active PTX molecules (Figure 
2C). By contrast, PTX-S-S-OA/TPGS2k NPs showed comparable cytotoxicity with Taxol, 
despite of the slightly delayed release of the PTX in tumor cells. These results confirm our 
hypothesis that the poor clinical outcomes of ester prodrugs of PTX and fatty acid could be 
attributed to the extremely slow drug release from ester prodrugs (PTX-DHA and PTX-OA). 
The cytotoxicity of prodrug nanoassemblies highly depends on the release rate of active 
PTX molecules from prodrugs.
2.5 Cellular Uptake of Prodrug Nanoassemblies
To investigate the cellular uptake, KB-3-1 were incubated with free coumarin-6 (C-6) or 
C-6-labeled prodrug NPs for different periods of time. After 0.5 h or 2 h of incubation, the 
cells were observed using confocal microscopy, and the intracellular fluorescence intensity 
was quantified by Flow Cytometry. As shown in Figure 3B–3D, both C-6-PTX-OA/TPGS2k 
NPs and C-6-PTX-S-S-OA/TPGS2k NPs exhibited much stronger intracellular fluorescence 
intensity at 0.5 h and 2 h compared to free C-6, and the intracellular fluorescence intensity 
significantly increased with time. This indicates that prodrug nanoassemblies elicit a 
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significantly higher cellular uptake than the free drug. Interestingly, C-6-PTX-S-S-OA/
TPGS2k NPs showed much higher intracellular fluorescence intensity than that of C-6-PTX-
OA/TPGS2k NPs, despite their similar nanostructure. Indeed, small-molecule prodrug-
nanosystem is quite unique, in which prodrugs themselves perform as the carrier materials. 
Moreover, encapsulation of fluorescent agents into NPs could lead to fluorescence 
quenching caused by the aggregation-caused quenching (ACQ) effect.[29] After 
internalization into tumor cells, most C-6 was trapped in C-6-PTX-OA/TPGS2k NPs owing 
to the high stability of PTX-OA. In contrast, due to the hydrolysis of PTX-S-S-OA in tumor 
cells, C-6-PTX-S-S-OA/TPGS2k NPs disassembled and released free C-6. As a result, C-6-
PTX-S-S-OA/TPGS2k NPs showed higher fluorescence intensity than that of C-6-PTX-OA/
TPGS2k NPs.
2.6 Pharmacokinetics
Pharmacokinetics were studied in Sprague Dawley (SD) rats. Taxol, the non-PEGylated 
prodrug nanoassemblies (PTX-OA NPs and PTX-S-S-OA NPs), and the PEGylated prodrug 
nanoassemblies (PTX-OA/TPGS2k NPs and PTX-S-S-OA/TPGS2k NPs) were intravenously 
administrated at an equivalent PTX dose of 5 mg kg−1. As shown in Figure 4, S6 and S7, the 
non-PEGylated formulations were quickly cleared from blood. The highly hydrophobic 
surface of non-PEGylated prodrug NPs would lead to rapid identification and phagocytosis 
by the reticulo-endothelial system (RES). On the other hand, the PEGylated formulations 
demonstrated significantly prolonged blood-circulation compared to Taxol and the non-
PEGylated formulations (Figure 4 and Table S3), owing to the PEG shielding on the outer 
surface of prodrug NPs. Furthermore, the ester prodrug (PTX-OA) significantly delayed the 
metabolic process of PTX due to its high chemical stability.[18]. As a result, PTX-OA/
TPGS2k NPs exhibited significantly prolonged blood circulation when compared to PTX-S-
S-OA/TPGS2k NPs, and most of them were in the form of prodrug (PTX-OA) in blood.
2.7 In vivo Biodistribution
We then investigated the biodistribution of prodrug nanoassemblies in KB-3-1 tumor bearing 
nude mice. Noninvasive optical imaging system (IVIS) was applied for visualization and 
calculation. When the tumor volume reached 500 mm3, the mice were administrated 
intravenously with free DiR and DiR-labeled prodrug nanoassemblies. As shown in Figure 
5, free DiR group showed high fluorescent intensity in lung, but very small amount of dye 
was accumulated in tumor at 24 h. By contrast, both DiR-labeled PTX-S-S-OA/TPGS2k NPs 
and DiR-labeled PTX-OA/TPGS2k NPs demonstrated strong fluorescent signal in tumor at 
24 h, suggesting that prodrug nanoassemblies could successfully accumulate in tumor via 
passive targeting (EPR effect).
2.8 In Vivo Anticancer Efficacy of Prodrug Nanoassemblies in Solid Tumor
Mice bearing KB-3-1 tumors were used to evaluate the in vivo antitumor efficacy of the 
prodrug nanoassemblies. As shown in Figure 6A and 6B, compared with PBS group and 
PTX-OA/TPGS2k NPs group, Taxol showed a moderate antitumor effect with delayed tumor 
progression. In contrast, the mice treated with PTX-S-S-OA/TPGS2k NPs exhibited a 
significant decrease in tumor volume, with the tumor almost completely disappearing at the 
end of treatment (Figure 6B and 6C). Notably, PTX-OA/TPGS2k NPs exhibited poor 
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antitumor activity, showing no significant difference compared with the untreated control 
group (PBS). The inferior therapeutic effect of PTX-OA/TPGS2k NPs could be ascribed to 
its extremely slow release rate of free PTX, despite its long blood circulation (Figure 4) and 
high accumulation in tumor (Figure 5). On the other hand, the potent antitumor efficacy of 
PTX-S-S-OA/TPGS2k NPs could be attributed to several aspects: (i) good colloidal stability 
after PEGylation; (ii) long blood circulation time; (iii) high accumulation in tumor via EPR 
effect, owing to suitable size (~100 nm) and long-term blood circulation; (iv) efficient 
cellular uptake; and (v) rapid and differential release of active PTX molecules within tumor 
cells. These aspects cover almost all stages of drug delivery following intravenous 
administration, resulting in potent chemotherapeutic efficacy with decreased off-target 
toxicities.
TUNEL assay was used to evaluate whether Taxol, PTX-OA/TPGS2k NPs and PTX-S-S-
OA/TPGS2k NPs induced apoptosis of tumor cells (Figure 6D and 6E). Significant PTX-
induced apoptosis was observed in mice treated with Taxol (22.2%) and PTX-S-S-OA/
TPGS2k NPs (64.1%), compared with that of PTX-OA/TPGS2k NPs (4.2%). Additionally, 
no significant change in body weight and the hematological parameters was observed in all 
the mice (Figure 7), Furthermore, no noticeable histological changes were observed in H&E-
stained tissue sections of organs (Figure S8). This suggests that the redox-sensitive prodrug-
nanosystem with potent antitumor activity elicited no significant off-target toxicities to 
major organs and tissues.
3. Conclusion
To develop advanced Nano-DDS for PTX delivery, we herein report a precisely self-
assembled tumor-stimuli-responsive prodrug-nanosystem based on a disulfide bond inserted 
conjugate of PTX and oleic acid (OA) for improved chemotherapeutic efficacy. We designed 
a novel redox-responsive conjugates by bridging PTX and OA with disulfide bond (PTX-S-
S-OA). An ester prodrug (PTX-OA) was used as the non-sensitive control. More 
interestingly, we found that both PTX-S-S-OA and PTX-OA could self-assembly into NPs. 
PEGylation with TPGS2k was utilized to achieve high stability and long blood-circulation of 
the prodrug nanoassemblies. As a result of the tumor-stimuli-triggered drug release, PTX-S-
S-OA/TPGS2k NPs exhibited distinct superiority over both Taxol and PTX-OA/TPGS2k 
NPs, with the tumor almost completely disappearing in mice after the last treatment. Such a 
uniquely engineered small-molecule nanoprodrug-system with redox-responsive drug 
release provides great potential for further improving the chemotherapy of hydrophobic 
anticancer drugs.
4. Experimental Section
Materials
PTX was purchased from NanJing Jingzhu Bio-technology Co. Ltd, China. Paclitaxel 
injection (Taxol) was purchased from Hospira Australia Pty Ltd. Oleic acid (OA), 
dithiothreitol (DTT), ethylene glycol, phenylmethanesulfonyl fluoride (PMSF) and N-
ethylmaleimide (NEM) were purchased from Aladdin, Shanghai, China. N,N’-
dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyrideine (DMAP) were obtained 
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from Pukang Pharm Co. Ltd. (Zhejiang, China). Cell culture media RPMI 1640, DMEM, 
penicilline-streptomycin, and fetal bovine serum were purchased from GIBCO, Invitrogen 
Corp. (Carlsbad, California, USA). Hoechst 33342 was purchased from BD Biosciences, 
USA. 3-(4,5-dimthyl-2-thiazolyl)-2,5-dipphenyl-2H-terazolium bromide (MTT) and trypsin-
EDTA were purchased from Sigma-Aldrich, USA. TUNEL assay kit was purchased from 
Promega, Madison, WI. VECTASHIELD with DAPI was purchased from Vector 
laboratories, Burlingame, CA. DiR was purchased from Life Technologies, USA. 
Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS2k) was synthesized according to our 
previous method.[30] All other chemicals and solvents utilized in this study were analytical 
or HPLC grade.
Synthesis of Conjugates
See the synthesis methods in Supporting Information.
Preparation and Characterization of Prodrug Nanoassemblies
8 mg of conjugates (PTX-S-S-OA or PTX-OA) and 1.2 mg of TPGS2k were dissolved in 1 
mL of ethanol. The mixture solution was added dropwise into 4 mL deionized water under 
stirring (800 rpm). Self-assembly of NPs occurred readily. Ethanol in the nanosystems was 
then evaporated under vacuum at 30 °C. The nanoassemblies (PTX-S-S-OA NPs and PTX-
OA NPs) without PEGylation were prepared similarly except for without adding TPGS2k. 
Dye-labeled prodrug NPs were prepared similarly by co-assembling coumarin-6 or DiR with 
prodrugs in aqueous medium. The size, size distribution and zeta potential of the prodrug 
nanoassemblies were measured using Zetasizer (Nano ZS, Malvern Co., UK), and the 
measurements were repeated in triplicate. Additionally, the morphology of the 
nanoassemblies was observed by JEOL 100CX II transmission electron microscopy (TEM) 
(JEOL, Japan). Samples were stained with 2% uranyl acetate.
Colloidal Stability of Prodrug Nanoassemblies
The colloidal stability of non-PEGylated prodrug nanoassemblies and PEGylated prodrug 
nanoassemblies was evaluated by determining the mean diameter of the NPs. To investigate 
the stability under simulated physiological condition, prodrug nanoassemblies at a final 
concentration of 0.25 mg mL−1 were incubated in PBS (pH 7.4) supplemented with 10% of 
fetal bovine serum (FBS) for 12 h at 37 °C. To explore the long-term stability of the prodrug 
nanoassemblies, PTX-OA/TPGS2k NPs (2 mg/mL) and PTX-S-S-OA/TPGS2k NPs (2 mg 
mL−1) were stored at 4 °C for three months. The particle size was determined at timed 
intervals by DLS.
In Vitro Hydrolysis of PTX from Prodrug Nanoassemblies
PTX hydrolyzed from prodrug NPs was determined by utilizing ethanol-containing PBS (pH 
7.4) as the release medium. The particle dispersions (200 mg PTX equivalent) were 
incubated in 30 mL of release medium at 37 °C. At timed intervals, the derived PTX was 
determined by high performance liquid chromatography (HPLC), and the concentration of 
free PTX was obtained by using standard curves from the total peak area of the absorbance 
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at 227 nm. The in vitro hydrolysis of PTX from prodrug nanoassemblies in the presence of 
DTT was carried out similarly, except for the addition of DTT to the release medium.
Cell Culture
Human epidermoid carcinoma (KB-3-1), human lung carcinoma cell line (H460), and 
human ovarian carcinoma cell line (OVCAR-8) were obtained from University of North 
Carolina at Chapel Hill (UNC-CH) Tissue Culture Facility (TCF). The cells were cultured in 
RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100 
units/mL) and streptomycin (100 µg mL−1) in a humidified atmosphere of 5% CO2 at 37 °C.
Cytotoxicity Evaluation
The in vitro cytotoxicity of Taxol and prodrug nanoassemblies was investigated by MTT 
viability assay on KB-3-1, H460, and OVCAR-8 cell lines. Briefly, cells were incubated in 
100 µL of complete culture medium in 96-well plates at a density of 5000 cells/well for 24 
h. After pre-incubation, the cells were exposed to serial dilutions of Taxol, PTX-S-S-OA/
TPGS2k NPs and PTX-OA/TPGS2k NPs, and further incubated for 48 h and 72 h. Untreated 
cells were utilized as control. At the end of the incubation, 20 µL of MTT (5 mg mL−1) was 
added, and the plates were incubated for additional 3 h at 37 °C. The medium was then 
discarded, and the formed formazan crystals were dissolved in DMSO (200 µL). The 
absorbance in each individual well was determined at the wavelength of 570 nm with a 
multidetection microplate reader (Plate CHAMELEON V-Hidex). Each drug concentration 
was tested in triplicate.
Cellular Uptake
Cellular uptake was carried out on KB-3-1 cells. Cells were seeded in 12-well plates 
containing 1 mL of media at a density of 1 × 105 cells/well for 24 h. The medium was 
replaced with fresh medium containing free coumarin-6, coumarin-6-labled PTX-S-S-OA/
TPGS2k NPs or PTX-OA/TPGS2k NPs with equivalent coumarin-6 concentration of 200 ng 
mL−1 for 0.5 h or 2 h at 37 °C. And the cells without any treatment were utilized as control. 
The cells were washed thrice with iced PBS, and the nuclei were counterstained by Hoechst 
33342. Cells in culture medium were observed by using an Eclipse Ti-U inverted 
microscope (Nikon Corp., Tokyo, Japan).
For quantitative analysis, the cells were washed, harvested and suspended in PBS after 
incubation with free coumarin-6 or coumarin-6-labeled prodrug nanoassemblies. Untreated 
cells were utilized as control. Cellular uptake was analyzed by flow cytometry on a BD 
FACSCalibur instrument (Becton Dickinson).
Pharmcokinetics
According to the Guide for Care and Use of Laboratory Animals of Shenyang 
Pharmaceutical University, Sprague-Dawley rats (200–250 g) were utilized for the 
pharmacokinetics studies. All rats were randomly assigned to five treatment groups (n=6). 
Taxol, PTX-OA/TPGS2k NPs, PTX-OA NPs, PTX-S-S-OA/TPGS2k NPs, and PTX-S-S-OA 
NPs were administrated by intravenous (I.V.) injection with an equivalent PTX dose of 5 mg 
kg−1. At timed intervals, about 0.3 mL blood was collected and centrifuged. The 
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concentration of prodrugs and free PTX in plasma was analyzed by a validated UPLC-MS-
MS method on an ACQUITY UPLC™ system (Waters Co., Ltd., Milford, MA, USA).
Biodistribution
The biodistribution of prodrug nanoassemblies was investigated in KB-3-1 tumor-bearing 
nude mice (n=3). Until the tumor volume reached ~500 mm3, mice were intravenously 
administrated with DiR solution, DiR labeled PTX-OA/TPGS2k nanoassemblies and DiR 
labeled PTX-S-S-OA/TPGS2k nanoassemblies at an equivalent DiR dose of 1 mg kg−1. At 4 
h or 24 h post injection, the mice were sacrificed for the observation of DiR accumulation in 
major organs and tumors by applying IVIS imaging system.
In Vivo Antitumor Activity
KB-3-1 cells (1 × 106 cells/100 µL) were inoculated subcutaneously to the female nude 
mice. When the tumor size was approximately 100 mm3, KB-3-1 xenografts tumor-bearing 
nude mice were randomized to four groups (five mice per group): untreated control (PBS), 
free PTX (Taxol), PTX-OA/TPGS2k NPs and PTX-S-S-OA/TPGS2k NPs. These 
formulations were administrated through tail veins every other day for a total of five 
injections with an equivalent PTX dose of 8 mg kg−1. Tumor volume and body weight were 
measured every day. Mice were sacrificed one day post-final injection, and serum was 
collected. The activities of aspartate transaminase (AST), alanine transaminase (ALT), blood 
urea nitrogen (BUN) and creatinine were assayed as indicators of hepatic and renal function. 
The tumor and major organs were collected and sectioned for further pathological study. 
Tumor cell apoptosis was then investigated by TdT-dependent dUTP-biotin nick end 
labeling (TUNEL) assay using an apoptosis detection kit (Promega, Madison, WI) according 
to the manufacturer’s instructions, and tumor sections were stained by Hoechst 33342. All 
staining samples were observed with an Eclipse Ti-U inverted microscope (Nikon Corp., 
Tokyo, Japan). The formalin-embedded tissues were stained by hematoxylin and eosin 
(H&E) to identify the pathological change of major organs.
Statistical Analysis
All acquired data were presented with an average values and its standard deviation, shown as 
mean ± SD. Student’s t-test and one-way analysis of variance (ANOVA) were utilized to 
analyze the differences of the groups, and P < 0.05 was considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
(A) Chemical structures of PTX-OA and PTX-S-S-OA. (B) Schematic illustration of the 
assembly of PEGylated prodrug NPs. (C) TEM images of PTX-OA NPs, PTX-OA/TPGS2k 
NPs, PTX-S-S-OA NPs, and PTX-S-S-OA/TPGS2k NPs.
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Figure 2. 
(A) Schematic illustration of redox-responsive drug release of PTX-S-S-OA/TPGS2k NPs 
within tumor cells. (B) Redox-sensitive drug release mechanism of PTX-S-S-OA triggered 
by GSH (DTT). (C) PTX release from PTX-S-S-OA/TPGS2k NPs or PTX-OA/TPGS2k NPs.
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Figure 3. 
(A) Representative dose-response curves of the MTT assays to KB-3-1 cell after 48 h 
treatment. (B) Flow cytometry results of cellular uptake in KB-3-1 cells after incubation 
with free C-6 or C-6-labeled prodrug nanoassemblies for 0.5 h and 2 h. Confocal laser 
scanning microscopy (CLSM) images of KB-3-1 cells incubated with C-6-Sol or C-6-
labeled prodrug nanoassemblies (200 µg mL−1 equivalent C-6) for (C) 0.5h and (D)2 h. 
Difference from C-6-Sol group, ** P < 0.01, *** P < 0.001.
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Figure 4. 
In vivo plasma concentration-time profiles of Taxol, non-PEGylated prodrug nanoassemblies 
and PEGylated prodrug nanoassemblies following a single intravenous administration of 
5mg kg−1 (PTX equivalent). (n=6)
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Figure 5. 
In vivo distribution of DiR-labeled prodrug nanoassemblies (n=3). (A) Fluorescent imaging 
at 24 h. (B) Quantitative analysis of relative organ and tumor accumulation at 24 h. Data 
were analyzed by IVIS spectrum small-animal in vivo imaging system, error bars represent 
± S.D.
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Figure 6. 
In vivo antitumor activity of prodrug nanoassemblies against KB-3-1 xenograft tumors 
(n=5). (A) Tumor growth curves after injected with different formulations. (B) Pictures of 
tumors after last treatment. (C) Tumor burden, the weight of tumors was divided by the 
average body weight of mice. (D) TUNEL assay quantitative results of tumor sections 
treating with different formulations by Image J software (n=3). (E) TUNEL assay pictures of 
tumor sections treating with different formulations, scale bar represents 500 µm. The data 
are presented as means ± SD, * P < 0.05, ** p < 0.01 and *** P < 0.001.
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Figure 7. 
(A) Body weight changes and (B) hepatic and renal function indicators of mice bearing 
KB-3-1 tumor xenografts after treatment. (n=5)
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